PURPOSE: A phase II trial investigated the activity and @entity137 of a bolus administration schedule of @entity901 , @entity1487 ( @entity1487 ), and @entity4181 (LV) therapy in @entity1 with untreated advanced @entity14 . @entity1 AND METHODS: Forty-five @entity1 in this multicenter, open, nonrandomized study received @entity901 130 mg/m(2) on the first day of each course and @entity1487 and LV 350 mg/m(2) and 20 mg/m(2), respectively, as a daily bolus for 5 days, every 21 days, for a maximum of six courses. RESULTS: Partial responses occurred in 18 @entity1 , giving an intent-to-treat response rate of 40.0%. Median time to response was 12.7 weeks; median duration of response was 18.4 weeks. Median progression-free survival was 5.9 months; median survival was 14 months. The independent prognostic factors for improved overall survival were good performance status and negative carcino-embryonic antigen blood level. Incidences of adverse effects were reduced after the @entity1487 dose was reduced to 300 mg/m(2). Reversible @entity137 occurred in 44.4% of @entity1 . CONCLUSION: Bolus administration of @entity901 , @entity1487 , and LV as first-line therapy for untreated advanced @entity14 is efficacious and safe. In addition to a more favorable safety profile, the 300 mg/m(2) dosage offered improved dose-intensity compared with the initial dosage.

Bolus @entity1487 and @entity4181 with XXXX as first-line treatment in metastatic @entity14 .

@entity901 :: ('MESH:C030110', 'Chemical') :: ['oxaliplatin'] @entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS'] @entity4181 :: ('MESH:D002955', 'Chemical') :: ['leucovorin'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'neurologic toxicity'] @entity14 :: ('MESH:D015179', 'Disease') :: ['colorectal cancer'] @entity1487 :: ('MESH:D005472', 'Chemical') :: ['5-FU', 'fluorouracil']
@entity901 :: (MESH:C030110,Chemical) :: ['oxaliplatin']
